Holen Sie sich die Stockscreener-App
1,070.16
0.99%
10.46
Handel nachbörslich:
1066.73
-3.43
-0.32%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,059.70
Offen:
$1056.77
24-Stunden-Volumen:
5.47M
Relative Volume:
1.44
Marktkapitalisierung:
$1.01T
Einnahmen:
$59.42B
Nettoeinkommen (Verlust:
$18.41B
KGV:
52.93
EPS:
20.2197
Netto-Cashflow:
$6.44B
1W Leistung:
+4.74%
1M Leistung:
+29.65%
6M Leistung:
+49.94%
1J Leistung:
+43.07%
1-Tages-Spanne:
$1,049.38
$1,075.72
1-Wochen-Bereich:
$1,014.01
$1,075.72
52-Wochen-Spanne:
$623.78
$1,075.72
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,070.16 | 948.45B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.05 | 491.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.51 | 417.60B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.54 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.40 | 242.64B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly Joins the Trillion-Dollar Club, Powered by Blockbuster Weight-Loss Drugs - NAI500
Lilly to highlight breast cancer treatment advances at SABCS 2025 - Investing.com
Health Care Stocks Edge Up As Biotech Shines And Eli Lilly Gets A Nod - Finimize
Inside Eli Lilly’s Alzheimer’s campaign blitz during holiday season - Campaign US
GLP-1 boom makes Eli Lilly the first $1 trillion pharma company - eMarketer
Lilly to present data from two phase 3 studies of Jaypirca in CLL at ASH By Investing.com - Investing.com South Africa
Eli Lilly’s Becomes Pharma’s First $1 Trillion Company - Oncodaily
Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is the best buy from here? - CNBC
Eli Lilly (LLY) to Present Key Findings on Jaypirca at Hematology Meeting - GuruFocus
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting - Eli Lilly and Company
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club - Yahoo Finance
Eli Lilly (LLY) Target Price Raised by Morgan Stanley to $1290 | LLY Stock News - GuruFocus
Eli Lilly Gets A Market Share Edge In The GLP-1 Race - Finimize
Eli Lilly, Novo Nordisk and Waltz Health collaborate on access to obesity drugs - Healthcare Finance News
Price Target on Eli Lilly Stock (LLY) Raised to $1,300 at Bernstein - TipRanks
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data? - Benzinga
Bernstein Raises Price Target for Eli Lilly (LLY) Amid Outperfor - GuruFocus
Eli Lilly soars to historic $1 trillion valuation first - Rolling Out
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity - Benzinga
Bernstein SocGen reiterates Eli Lilly stock rating with $1,300 price target - Investing.com Australia
Eli Lilly Becomes First Trillion-Dollar Health Company | Health | rochsent.com - The Rochester Sentinel
Lilly hits trillion-dollar valuation as GLP-1 era peaks - statnews.com
Eli Lilly Becomes First Trillion-Dollar Health Company - mydailyrecord.com
Getting Big by Selling Slim – Eli Lilly’s Rise to $1 Trillion - Carson Group
Bernstein raises Eli Lilly stock price target to $1,300 on Orforglipron launch - Investing.com India
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally - TradingView
Stock Movers: Alphabet, Eli Lilly, RTX - Bloomberg.com
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in - Nasdaq
Morgan Stanley raises Eli Lilly stock price target to $1,290 on GLP-1 market growth - Investing.com
Eli Lilly stock falls, Biogen rises after Novo’s Alzheimer’s trial failure - Investing.com
Eli Lilly Stock Surges 33% in 2025, Tops $1 Trillion Market Cap - TIKR.com
Eli Lilly: Moving To 'Strong Buy' Rating On Revenue Growth Beyond Zepbound (NYSE:LLY) - Seeking Alpha
Eli Lilly & Co. (LLY) Stock: Surges as Company Hits Historic $1 Trillion Market Cap - CoinCentral
These Stocks Are Moving the Most Today: Tesla, Alphabet, Strategy, Eli Lilly, and More - MSN
Bernstein Adjusts PT on Eli Lilly and Co. to $1,300 From $1,100, Maintains Outperform Rating - MarketScreener
Lilly becomes first $1trn+ pharma company - pharmaphorum
Nobel laureate Carolyn Bertozzi to rejoin Lilly board - Endpoints News
In Q3, drugmakers saw a marked decline in US vaccine sales as Eli Lilly kicked into higher gear - Fierce Pharma
Eli Lilly becomes first pharmaceutical company to reach USD 1trn market value - medwatch.com
Lilly plans to open Lilly Gateway Labs site in Philadelphia - Medical Dialogues
Lilly levels up Alzheimer’s awareness with Chris Hemsworth collab, major media buys - Fierce Pharma
Eli Lilly Reaches $1 Trillion Valuation - Sharecafe
Eli Lilly & Co. Set to Open New Lilly Gateway Labs Incubator in Philadelphia, Its Fifth in the Nation - PHILADELPHIA.Today
Eli Lilly to Launch a GLP-1 Pill to Rival Ozempic, but There’s a Catch - Inc.com
Futures Due, Bitcoin Rises, But Wait For This - Investor's Business Daily
Fisher Asset Management LLC Boosts Stake in Eli Lilly - TipRanks
Coatue Management Reduces Stake in Eli Lilly - TipRanks
PRIMECAP Management Co Reduces Stake in Eli Lilly - TipRanks
Gilder Gagnon Howe Reduces Stake in Eli Lilly - TipRanks
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? - AOL.com
Eli Lilly Stock Price ForecastLLY Shares Hits $1T Market as GLP-1 Sales Surge 54% and EPS Jumps 495% - TradingNEWS
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
2.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):